Response to US study of CAR-T in childhood brain tumors
On 14 November 2024 Dutch national newspaper De Volkskrant writes about an American study into CAR-T for children with a brain tumor, and also features comment from Jasper van der Lugt and Friso Calkoen, pediatric oncologists at the Princess Máxima Center.
One of the eleven children and young adults with the incurable brain tumor DIPG who received CAR-T cell therapy appears to have been cured. Four years after the treatment, this 20-year-old young man is still alive. Nine of the eleven children in the study saw an improvement in their symptoms. In four of them, the tumor shrank. The average survival time increased by seven months. The study was published in Nature today.
Read the article in De Volkskrant here (behind a paywall).
Dr. Jasper van der Lugt, pediatric oncologist specializing in brain tumors, says: ‘The results are promising, but I am cautious. You had to be well enough and your tumor had to be small enough to take part in this study. And many of the children and young people in the study had received radiation shortly before the CAR-T cell therapy. That makes it hard to untangle the effect of the radiotherapy and the CAR-T treatment.
‘All children and young people in the study experienced serious side effects. With an incurable brain tumor, you sometimes take more risks, but it remains a precarious balance. Children with DIPG usually do not have long to live. It is important to carefully weigh the pros and cons of participating in a study of a new treatment. At the Máxima, we hope to open our own clinical trial at the end of next year into another type of CAR-T for children with a brain tumor, including DIPG.’
Dr. Friso Calkoen, pediatric oncologist specialized in CAR-T, adds: ‘So far, CAR T-cells have mainly worked on forms of blood cancer, such as leukemia. It is more difficult to get them to work in tumors in organs or tissues, because they have a kind of protective wall around them. They are also more difficult to distinguish from healthy tissue around them. All over the world, including here at the Princess Máxima Center, scientists are studying whether this promising form of immunotherapy can also work for brain and solid tumors.’
Are you participating in the Utrecht Marathon or are you a keen runner? Register for the Running Symposium on March 19th.
On Sunday, May 31st, Utrecht Science Park will once again be the setting for the Utrecht Marathon. Thousands of runners will line up at the starting line to achieve a fantastic feat: running a quarter, half, or full marathon! To help you prepare optimally, the Utrecht Science Park Foundation, in collaboration with partners Utrecht University, UMC Utrecht, Utrecht University of Applied Sciences, and Olympos Sports Centre, is organizing a running symposium where you’ll be informed and inspired to get the most out of your running performance.
Applications Now Open for UtrechtInc Validation Programmes
Have you ever wondered what it takes to turn research or an idea into a startup? The validation programmes offered by UtrechtInc may provide the first step. Applications are now open.
Relocating a Rainforest: Behind the Scenes at the Botanic Gardens
The Tropical greenhouses at the Utrecht University Botanic Gardens are among its most beloved attractions. But after decades of service, they are ready for retirement and the decision has been made to replace them. Replacing the Greenhouses is far more complex than tearing down glass and steel. It means temporarily relocating, and later returning, thousands of living plants. How do you even begin to move a rainforest?
Utrecht Science Park researchers receive prestigious Cancer Grand Challenge grants
Several research groups, including researchers from UMC Utrecht, the Princess Máxima Center, and the Hubrecht Institute, have been selected for a prestigious Cancer Grand Challenge (CGC) grant. Cancer Grand Challenges was co-founded in 2020 by Cancer Research UK and the National Cancer Institute in the United States. The initiative supports international, multidisciplinary research teams focusing on major challenges in cancer research.